About viridian therapeutics - VRDN
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
VRDN At a Glance
Viridian Therapeutics, Inc.
221 Crescent Street
Waltham, Massachusetts 02453
| Phone | 1-617-272-4600 | Revenue | 302.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -208,560,000.00 | |
| Sector | Health Technology | Employees | 143 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
VRDN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4,309.177 |
| Price to Book Ratio | 3.216 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.672 |
| Enterprise Value to Sales | 2,634.991 |
| Total Debt to Enterprise Value | 0.029 |
VRDN Efficiency
| Revenue/Employee | 2,111.888 |
| Income Per Employee | -1,458,461.538 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.00 |
VRDN Liquidity
| Current Ratio | 15.425 |
| Quick Ratio | 15.425 |
| Cash Ratio | 14.989 |
VRDN Profitability
| Gross Margin | -310.596 |
| Operating Margin | -99,018.212 |
| Pretax Margin | -89,387.086 |
| Net Margin | -69,059.603 |
| Return on Assets | -33.834 |
| Return on Equity | -37.455 |
| Return on Total Capital | -30.02 |
| Return on Invested Capital | -36.038 |
VRDN Capital Structure
| Total Debt to Total Equity | 3.439 |
| Total Debt to Total Capital | 3.324 |
| Total Debt to Total Assets | 3.111 |
| Long-Term Debt to Equity | 4.678 |
| Long-Term Debt to Total Capital | 3.25 |